The clinical impact of using complex molecular profiling strategies in routine oncology practice.


Por: Laes JF, Aftimos P, Barthelemy P, Bellmunt J, Berchem G, Camps C, Peñas RL, Finzel A, García-Foncillas J, Hervonen P, Wahid I, Joensuu T, Kathan L, Kong A, Mackay J, Mikropoulos C, Mokbel K, Mouysset JL, Odarchenko S, Perren TJ, Pienaar R, Regonesi C, Alkhayyat SS, El Kinge AR, Abulkhair O, Galal KM, Ghanem H, El Karak F, Garcia A, Ghitti G, Sadik H

Publicada: 17 abr 2018
Categoría: Oncology

Resumen:
Molecular profiling and functional assessment of signalling pathways of advanced solid tumours are becoming increasingly available. However, their clinical utility in guiding patients' treatment remains unknown. Here, we assessed whether molecular profiling helps physicians in therapeutic decision making by analysing the molecular profiles of 1057 advanced cancer patient samples after failing at least one standard of care treatment using a combination of next-generation sequencing (NGS), immunohistochemistry (IHC) and other specific tests. The resulting information was interpreted and personalized treatments for each patient were suggested. Our data showed that NGS alone provided the oncologist with useful information in 10-50% of cases (depending on cancer type), whereas the addition of IHC/other tests increased extensively the usefulness of the information provided. Using internet surveys, we investigated how therapy recommendations influenced treatment choice of the oncologist. For patients who were still alive after the provision of the molecular information (76.8%), 60.4% of their oncologists followed report recommendations. Most treatment decisions (93.4%) were made based on the combination of NGS and IHC/other tests, and an approved drug- rather than clinical trial enrolment- was the main treatment choice. Most common reasons given by physicians to explain the non-adherence to recommendations were drug availability and cost, which remain barriers to personalised precision medicine. Finally, we observed that 27% of patients treated with the suggested therapies had an overall survival 12 months. Our study demonstrates that the combination of NGS and IHC/other tests provides the most useful information in aiding treatment decisions by oncologists in routine clinical practice.

Filiaciones:
Laes JF:
 Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Aftimos P:
 Institut Hospital del Mar d'Investigacions Médiques, Barcelona, Spain

Barthelemy P:
 Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Bellmunt J:
 Institut Hospital del Mar d'Investigacions Médiques, Barcelona, Spain

 Harvard University, Cambridge, Massachusetts, USA

Berchem G:
 Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg

Camps C:
 Consorcio Hospital General Universitario de Valencia, Valencia, Spain

Peñas RL:
 Consorcio Hospitalario Provincial de Castellón, Castellón, Spain

Finzel A:
 Hôpitaux Universitaires de Strasbourg, Strasbourg, France

García-Foncillas J:
 Fundación Jimenez Díaz, IDC Salud, Madrid, Spain

Hervonen P:
 Docrates Cancer Center, Helsinki, Finland

Wahid I:
 Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia

Joensuu T:
 Docrates Cancer Center, Helsinki, Finland

Kathan L:
 Cancercare, Cape Town, South Africa

Kong A:
 University Hospital Birmingham NHS Trust, University of Birmingham, Edgbaston, UK

Mackay J:
 The London Breast Clinic, London, UK

Mikropoulos C:
 Kent Oncology Centre, Kent, UK

Mokbel K:
 The Princess Grace Hospital, London, UK

Mouysset JL:
 Clinique Rambot-Provençale, Aix-en-Provence, France

Odarchenko S:
 Vinnitsa Regional Clinical Oncology Center, Vinnitsa, Ukraine

Perren TJ:
 St. James University Hospital, Leeds, UK

Pienaar R:
 Cancercare, Cape Town, South Africa

Regonesi C:
 Clinica Las Condes, Santiago, Chile

Alkhayyat SS:
 King Abdulaziz University Hospital, Jeddah, Saudi Arabia

El Kinge AR:
 Specialized Medical Center Hospital, Riyadh, Saudi Arabia

Abulkhair O:
 Specialized Medical Center Hospital, Riyadh, Saudi Arabia

Galal KM:
 Kasr El-Aini Hospital, Cairo University, Cairo, Egypt

Ghanem H:
 Lebanese American University Medical Center-Rizk Hospital (LAUMC-RH), Beirut, Lebanon

El Karak F:
 Saint Joseph University, Hôtel-Dieu de France University Hospital, Beirut, Lebanon

Garcia A:
 Nuffield Hospital, Chester, UK

Ghitti G:
 Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Sadik H:
 Hôpitaux Universitaires de Strasbourg, Strasbourg, France
ISSN: 19492553





Oncotarget
Editorial
Impact Journals, Estados Unidos America
Tipo de documento: Article
Volumen: 9 Número: 29
Páginas: 20282-20293
ID de PubMed: 29755651

MÉTRICAS